Previously Dr. Martini worked at Shire plc in Lexington, Mass., as Senior Director of Discovery Biology and Translational Research, Mass., focusing
on fibrotic diseases of muscle, kidney, skin, lung, bone marrow and metabolic liver diseases, with particular emphasis on different therapeutic modalities for pathway modulation.
The firm dropped discovery and development in the areas of diabetes, virology, and neuroscience in favor of a research focus
on oncology, heart failure, genetically defined
diseases, immunoscience, and
fibrotic diseases.
In recent years, researchers have developed so - called «senolytic» drugs that wipe out senescent cells in aging mice and mouse models of age - related
disease, exploiting the high dependence of these cells
on specific biochemical survival pathways.9, 10 In these studies, senolytic drugs have restored exercise capacity9 and formation of new blood and immune precursor cells11 in aging mice to near youthful norms, and prevented or treated mouse models of
diseases of aging like osteoarthritis, 12
fibrotic lung
disease, 13 hair loss, 14 atherosclerosis, 15,16 and age - related
diseases of the heart itself.9 UNITY Biotechnology is leading a growing charge toward the clinic, with human clinical trials expected to begin in 2019.